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The neurodegenerative disease glaucoma is one of the leading causes of 
blindness and accounts for over ten million visits to physicians for treatment. 
Unfortunately, there is yet to be a concrete accepted approach to alleviating 
the effects of glaucoma. This dissertation examines recent studies and reports 
on the specifics of viral vectors, non-viral vectors, piezoelectric inkjet printing, 
heat inkjet printing, and glaucoma. A few of the studies involve the progression 
of an experiment while others combine and discuss the results of multiple 
experiments. Using these articles I compared the effectiveness of gene 
therapy to the use of inkjet printing to create retinal cells. By replacing, adding, 
or deleting a specific sequence in the human body, the gene expression of the 
eye can be altered. There are two different types of injections for gene 
therapy, viral vectors and non-viral vectors. Both methods typically target the 
trabecular meshwork and neuroretina to regulate the aqueous humor outflow 
and lower the intraocular pressure. In the case of glaucoma, the treatment 
solely provides neuroprotection instead of curing the disease, thus patients 
must undergo repeated injections in order to keep the disease from 
deteriorating. Inkjet printing of retinal cells have shown to produce three 
dimensional tissue grafts that may replace defective tissues. The printed cells 
have been tested for survivability and regeneration properties, since it has 
been suggested that the printing process can cause defects. Both heat inkjet 
printing and piezoelectric printing have been used to create neural cells. By 
evaluating the advantages and disadvantages of gene therapy as well as 
printing, I can evaluate whether or not inkjet printing can overtake gene 
therapy to become a conventional treatment for glaucoma in the near future. 
There have not been many clinical trials done on either of these methods for 
glaucoma, thus it is difficult to obtain a certain answer to the question at hand. 
At this point advancements in the area of three-dimensional printing neural 
sheets may provide a more promising cure. However, more research must be 
done on how each of these treatments affect glaucoma in humans. 
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Glaucoma is a neuropathy caused by the failure of the eye to regulate the 
balance between the amount of internal fluid produced and drained. The 
apoptosis of retinal ganglion cells (RGC) has been found to cause obstruction 
in the trabecular meshwork that drains the aqueous humor.This results in 
dangerously high levels of intraocular pressure (IOP) which will damage the 
optic nerve and cause vision loss. Currently, the top approach to treating 
glaucoma is medication used to lower the intraocular pressure. This method 
provides only temporary relief, since the intraocular fluid will build back up 
again within a short time span. Patients receive side-effects, such as ocular 
surface disease, from the medication and often do not comply with daily 
dosages. Thus, it is crucial to work towards a treatment with long-lasting 
outcomes, less side-effects, and more patient compliance. Researchers have 
used gene therapy to target the genes myocilin, optineurin, and WDR 36 in 
order to establish neuroprotection and to lower intraocular pressure. Inkjet 
printing and scaffolding of retinal ganglion cells, on the other hand, can be 
used to implant healthy RGCs into a patient. 
Gene therapy can be used to target specific parts within the eye, 
particularly the trabecular meshwork and neuroretina, using either viral or 
antiviral vectors. Targeting the trabecular meshwork would help regulate 
aqueous humor outflow and lower IOP. The trabecular meshwork’s 
morphology can be altered by the transduction of coenzyme3, but the 
transduction also leads to the disruption of increased outflow in the anterior 
segments. The growth factor TGF-β has been a target for gene therapy, as 
it affects cell migration and proliferation, consequently slowing the 
progression of glaucoma. Alternatively, targeting astrocytes, microglia and 
Muller cells could promote the survival of RGCs especially in the early 
stages of glaucoma. Gene therapy’s fallbacks lie in its intracellular and 
extracellular barriers to successful vector delivery. Piezoelectric or heat 
inkjet printing of retinal ganglion cells aims to replace the dead RGCs in 
the eye. The advantage of printing cells is that these RGCs can be printed 
in any pattern, ideally in one that mirrors the RGCs in the retina. These 
patterns subsequently can be made into a scaffold to implant into the eye. 
The main inquiry about this process is regarding the viability of the printed 
cells. Experiments using certain mediums and bio-papers have found that 
the electrophysiological and tensile properties of the printed cells remain 
intact, thus, capable to be implanted.
It is crucial to identify the strengths and weaknesses of advancing 
treatments for glaucoma before they are implemented on patients. 
• Gene therapy can lower intraocular pressure and provide 
neuroprotection for long periods.
• While gene therapy can insert vectors to stop the apoptosis of retinal 
ganglion cells, it lacks the concrete ability to regenerate the cells that 
went through apoptosis. 
• Printed RGCs can be made into scaffolds and are viable to be 
implanted into the tissue of the retina, acting as substitutes. 
• The printing of RGCs is a first step, the next step of implanting printed 
neural tissues must be experimented and evaluated. 
• It is difficult to conclude which is the better absolute treatment without 
further research done on the printing of cells, but the potential 
outcomes of printed RGCs indicate a more promising cure. 
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